Literature DB >> 16940064

Macrolide and azithromycin use are linked to increased macrolide resistance in Streptococcus pneumoniae.

Miika Bergman1, Solja Huikko, Pentti Huovinen, Pirkko Paakkari, Helena Seppälä.   

Abstract

The connection between regional rates of antimicrobial resistance in Streptococcus pneumoniae and regional antimicrobial use in Finland was investigated. During the 6-year study period of 1997 to 2002, a total of 31,609 S. pneumoniae isolates were tested for penicillin resistance and a total of 23,769 isolates were tested for macrolide resistance in 18 central hospital districts in Finland. The regional macrolide resistance rates were compared with the local use of (i) all macrolides pooled and (ii) azithromycin. The penicillin resistance levels were compared with the consumption data for (i) penicillins, (ii) cephalosporins, (iii) all beta-lactams pooled, and (iv) all macrolides pooled. A statistically significant association between macrolide resistance and total use of macrolides and the use of azithromycin was found. Moreover, total use of beta-lactams and total use of cephalosporins were significantly connected to low-level penicillin resistance. A statistically significant association between penicillin-nonsusceptible isolates and penicillin or total macrolide consumption was not found. In conclusion, total macrolide use and azithromycin use are associated with increased macrolide resistance, and beta-lactam use and cephalosporin use are connected to increased low-level penicillin resistance in S. pneumoniae. Unnecessary prescribing of macrolides and cephalosporins should be avoided.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16940064      PMCID: PMC1635217          DOI: 10.1128/AAC.00234-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  21 in total

Review 1.  What have we learned from pharmacokinetic and pharmacodynamic theories?

Authors:  J J Schentag; K K Gilliland; J A Paladino
Journal:  Clin Infect Dis       Date:  2001-03-15       Impact factor: 9.079

2.  Evolving resistance patterns of Streptococcus pneumoniae: a link with long-acting macrolide consumption?

Authors:  F Baquero
Journal:  J Chemother       Date:  1999-02       Impact factor: 1.714

3.  Prevalence and molecular genetics of macrolide resistance among Streptococcus pneumoniae isolates collected in Finland in 2002.

Authors:  M Rantala; S Huikko; P Huovinen; J Jalava
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

4.  Mathematical model--tell us the future!

Authors:  Pentti Huovinen
Journal:  J Antimicrob Chemother       Date:  2005-06-21       Impact factor: 5.790

5.  Emergence of macrolide and penicillin resistance among invasive pneumococcal isolates in Germany.

Authors:  Ralf René Reinert; Adnan Al-Lahham; Maria Lemperle; Christoph Tenholte; Claudia Briefs; Stefan Haupts; Hans Hubert Gerards; Rudolf Lütticken
Journal:  J Antimicrob Chemother       Date:  2002-01       Impact factor: 5.790

6.  Influence of macrolide antibiotics on promotion of resistance in the oral flora of children.

Authors:  U Kastner; J P Guggenbichler
Journal:  Infection       Date:  2001-10       Impact factor: 3.553

7.  Predicting antimicrobial resistance in invasive pneumococcal infections.

Authors:  Otto G Vanderkooi; Donald E Low; Karen Green; Jeff E Powis; Allison McGeer
Journal:  Clin Infect Dis       Date:  2005-03-31       Impact factor: 9.079

8.  Mechanisms by which antibiotics promote dissemination of resistant pneumococci in human populations.

Authors:  Matthew H Samore; Marc Lipsitch; Stephen C Alder; Bassam Haddadin; Greg Stoddard; Jacquelyn Williamson; Katherine Sebastian; Karen Carroll; Onder Ergonul; Yehuda Carmeli; Merle A Sande
Journal:  Am J Epidemiol       Date:  2005-11-30       Impact factor: 4.897

9.  Outpatient antibiotic use in Europe and association with resistance: a cross-national database study.

Authors:  Herman Goossens; Matus Ferech; Robert Vander Stichele; Monique Elseviers
Journal:  Lancet       Date:  2005 Feb 12-18       Impact factor: 79.321

10.  Community prescribing and resistant Streptococcus pneumoniae.

Authors:  Galia Barkai; David Greenberg; Noga Givon-Lavi; Eli Dreifuss; Daniel Vardy; Ron Dagan
Journal:  Emerg Infect Dis       Date:  2005-06       Impact factor: 6.883

View more
  39 in total

1.  A trial of clarithromycin for the treatment of suboptimally controlled asthma.

Authors:  E Rand Sutherland; Tonya S King; Nikolina Icitovic; Bill T Ameredes; Eugene Bleecker; Homer A Boushey; William J Calhoun; Mario Castro; Reuben M Cherniack; Vernon M Chinchilli; Timothy J Craig; Loren Denlinger; Emily A DiMango; John V Fahy; Elliot Israel; Nizar Jarjour; Monica Kraft; Stephen C Lazarus; Robert F Lemanske; Stephen P Peters; Joe Ramsdell; Christine A Sorkness; Stanley J Szefler; Michael J Walter; Stephen I Wasserman; Michael E Wechsler; Hong Wei Chu; Richard J Martin
Journal:  J Allergy Clin Immunol       Date:  2010-10       Impact factor: 10.793

2.  Blood, tissue, and intracellular concentrations of erythromycin and its metabolite anhydroerythromycin during and after therapy.

Authors:  S Krasniqi; P Matzneller; M Kinzig; F Sörgel; S Hüttner; E Lackner; M Müller; M Zeitlinger
Journal:  Antimicrob Agents Chemother       Date:  2011-11-14       Impact factor: 5.191

3.  Evaluation of the Do Bugs Need Drugs? program in British Columbia: Can we curb antibiotic prescribing?

Authors:  Rachel M McKay; Linda Vrbova; Elaine Fuertes; Mei Chong; Samara David; Kim Dreher; Dale Purych; Edith Blondel-Hill; Bonnie Henry; Fawziah Marra; Perry Rw Kendall; David M Patrick
Journal:  Can J Infect Dis Med Microbiol       Date:  2011       Impact factor: 2.471

4.  Therapeutic frontiers: preventing and treating infectious diseases by inhibiting bacterial quorum sensing.

Authors:  C A Martin; A D Hoven; A M Cook
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-03-06       Impact factor: 3.267

5.  Geographic and temporal trends in antimicrobial nonsusceptibility in Streptococcus pneumoniae in the post-vaccine era in the United States.

Authors:  Ruth Link-Gelles; Ann Thomas; Ruth Lynfield; Sue Petit; William Schaffner; Lee Harrison; Monica M Farley; Deborah Aragon; Megin Nicols; Pam Daily Kirley; Shelley Zansky; James Jorgensen; Billie Anne Juni; Delois Jackson; Matthew R Moore; Marc Lipsitch
Journal:  J Infect Dis       Date:  2013-07-12       Impact factor: 5.226

6.  Evaluation of programmatic changes to an antimicrobial stewardship program with house officer feedback.

Authors:  Steven Y Hong; Lauren H Epstein; Kenneth Lawrence; Lisa Davidson; Ying Taur; Lauren Nadkarni; Shira Doron
Journal:  J Eval Clin Pract       Date:  2012-03-15       Impact factor: 2.431

Review 7.  Integrated Multilevel Surveillance of the World's Infecting Microbes and Their Resistance to Antimicrobial Agents.

Authors:  Thomas F O'Brien; John Stelling
Journal:  Clin Microbiol Rev       Date:  2011-04       Impact factor: 26.132

Review 8.  Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases.

Authors:  P Zarogoulidis; N Papanas; I Kioumis; E Chatzaki; E Maltezos; K Zarogoulidis
Journal:  Eur J Clin Pharmacol       Date:  2011-11-22       Impact factor: 2.953

Review 9.  Multidrug-resistant Streptococcus pneumoniae infections: current and future therapeutic options.

Authors:  Françoise Van Bambeke; René R Reinert; Peter C Appelbaum; Paul M Tulkens; Willy E Peetermans
Journal:  Drugs       Date:  2007       Impact factor: 9.546

10.  Increase in pneumococcus macrolide resistance, United States.

Authors:  Stephen G Jenkins; David J Farrell
Journal:  Emerg Infect Dis       Date:  2009-08       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.